NCT01975519View on ClinicalTrials.gov

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

December 10, 2013

Primary Completion Date

March 11, 2019

Study Completion Date

March 11, 2019

Conditions
Advanced Soft Tissue Sarcoma
Interventions
DRUG

TRC105 and Pazopanib

Weekly TRC105 in combination with standard dose Pazopanib.

Trial Locations (9)

10029

Mount Sinai School of Medicine-Tisch Cancer Institute, New York

27710

Duke University, Durham

32224

Mayo Clinic Jacksonville, Jacksonville

35243

University of Alabama at Birmingham, Birmingham

55905

Mayo Clinic Rochester, Rochester

75230

Mary Crowley Cancer Research Center, Dallas

84112

University of Utah, Salt Lake City

90403

Sarcoma Oncology Center, Santa Monica

92122

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT01975519 - A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter